High-Density Lipoprotein (HDL) Treatment Study

June 2, 2008 updated by: McGill University Health Centre/Research Institute of the McGill University Health Centre

Treatment Study for Severe High-Density Lipoprotein Deficiency

A low level of plasma high-density lipoprotein (HDL) cholesterol, "the good cholesterol", is the most common lipid abnormality observed in patients with a premature atherosclerotic cardiovascular disease. HDL carry excess cholesterol from peripheral tissues to the liver to be metabolized or excreted, a process known as reverse cholesterol transport.

Epidemiological studies have shown an inverse correlation between plasma levels of HDL cholesterol and the risk of cardiovascular disease. An increase in plasma HDL cholesterol levels by 1 mg/dL may reduce the risk of cardiovascular disease by 2 to 3%. The standard care of treatment for a low level of HDL cholesterol is: 1) lifestyle modifications including exercise, smoking cessation, weight control, moderate alcohol intake and decreased dietary fat intake - all patients are encouraged to follow these lifestyle modifications; 2) medications which can raise HDL cholesterol.

Currently used medications to treat lipid disorders can increase, in some extent, HDL cholesterol. These include niacin (vitamin B3), fibric acid derivatives (fibrates) and statins. However there is no data on the effect of these medications on severe cases of HDL deficiency. This project aims to determine whether currently available medications, used in standard medical practice for the treatment of lipoprotein disorders, can substantially increase HDL cholesterol in severe cases of HDL deficiencies.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Objective and rationale. We have collected, in the past 15 years, a large group of patients with familial HDL cholesterol deficiency. In approximately 25% of index probands in our family studies, the genetic basis of HDL deficiency is identified at the molecular level. Approximately 20% of our severe HDL cholesterol deficient patients have mutations within the ABCA1 gene, while mutations at the apoA-I and SMPD1 genes have also been identified. In the present study, we wish to determine whether conventional lipid-regulating medication can substantially increase HDL cholesterol in patients with severe HDL deficiency. Anecdotal reports from our clinic suggest that patients with ABCA1 mutations do not respond to currently available medication; this will be more thoroughly ascertain in this protocol. In addition, examining patients with other genetic HDL deficiencies and familial forms (gene not yet identified) will provide insight on the treatment options for these patients. We feel it is important first whether currently recommended medication can effectively raise HDL cholesterol in these patients.

Study subjects. The subjects will include patients with familial HDL deficiency (HDL cholesterol < 5th percentile for age and gender, with at least one degree relative affected) and HDL deficiency with well-defined genetic mutation. We expect approximately 20-25 patients to enter the study.

Patients will be excluded if at least one of the following criteria is present:

  • Triglycerides ≥ 5 mmol/L
  • Diabetes
  • Severe obesity (BMI ≥ 30)
  • Alcohol intake > 21 drinks/week
  • Untreated disease (thyroid, hepatic or renal)

Study procedure. Patients will be treated according to current lipid treatment guidelines (McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemias and prevention of cardiovascular disease. Can J Cardiol 2006; 22:913-927) and the use of the three following medications (separately or in combination):

  • Lipitor 20 mg
  • Lipidil 200 mg
  • Niaspan 2 g

It should be noted that all three medications are currently used to treat patients with dyslipidemia and represent the current "standard of care".

Statistics. The null hypothesis expects that no treatment effect increases HDL cholesterol by 10% in the study sample (α = 0.05 and β = 0.8). Using this study design, each patient will serve as his/her own control. Differences between baseline (B) and treatment (T) periods for each medication will be examined by sudent's t-test.

Protocol. Each treatment period will last 8 weeks; wash-out periods will last 4 weeks. Baseline values (B1-3) will be taken at the beginning of each treatment period. On-treatment values (T1-3) will be drawn at the end of each medication period. At each time B (baseline) and T (after a treatment) patient will be examined for:

  • Body mass index (weight and height)
  • Blood pressure
  • Symptoms of ischemic heart disease
  • Hepatic functions
  • Myopathic symptoms

The following blood test will be performed:

  • Total cholesterol
  • Triglycerides
  • HDL cholesterol
  • LDL cholesterol
  • ApoA-I, apoB
  • ALT, CK

At time B1 blood will also be collected for the determination of:

  • TSH
  • Creatinine
  • ALT
  • Blood glucose

In addition, blood will be used to examine the ability of the patient's HDL and plasma to promote cellular cholesterol efflux, using an in vitro model which is well established in our laboratory. Cellular cholesterol efflux tests the efficiency of apoA-I lipidation from cells for the formation of HDL particles. This will provide a general index of the functional status of HDL particles in the body.

Study Type

Interventional

Enrollment (Actual)

19

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Quebec
      • Montreal, Quebec, Canada, H3A 1A1
        • MUHC-Royal Victoria Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

- HDL deficiency (HDL-cholesterol < 5th percentile, age and gender-matched)

Exclusion Criteria:

  • Triglycerides ≥ 5 mmol/L
  • Diabetes
  • Severe obesity (BMI ≥ 30)
  • Alcohol intake > 21 drinks/week
  • Untreated disease (thyroid, hepatic or renal)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
HDL cholesterol
Time Frame: 9 months
9 months

Secondary Outcome Measures

Outcome Measure
Time Frame
apo AI
Time Frame: 9 months
9 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2006

Primary Completion (Actual)

September 1, 2007

Study Completion (Actual)

September 1, 2007

Study Registration Dates

First Submitted

April 5, 2007

First Submitted That Met QC Criteria

April 6, 2007

First Posted (Estimate)

April 9, 2007

Study Record Updates

Last Update Posted (Estimate)

June 4, 2008

Last Update Submitted That Met QC Criteria

June 2, 2008

Last Verified

June 1, 2008

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MUHC-RI 0906

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Genetic Diseases, Inborn

Clinical Trials on Atorvastatin; Fenofibrate; Niacin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe